**Contents**

**Highlights of This Issue** 2593

**SPECIAL FEATURES**

**CCR Translations**

2595  
**Oncolytic Virotherapy Needs Trials, Not Access Programs**  
Kevin J. Harrington  
*See article, p. 2734*

**Molecular Pathways**

2598  
**Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells In Vivo**  
Ferdinando Pucci and Mikael J. Pittet

**CCR Focus**

2605  
**PFS: The Endpoint We Love and Love to Hate**  
Susan E. Bates

2607  
**Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors**  
Ronald L. Korn and John J. Crowley

2613  
**Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials**  
Rajeshwari Sridhara, Sumithra J. Mandrekar, and Lori E. Dodd

2621  
**The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival**  
Daniel Carl Sullivan, Lawrence H. Schwartz, and Binsheng Zhao

2629  
**The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement**  
Liza C. Villaruz and Mark A. Socinski

2637  
**Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials**  
Jenny J. Zhang, Lijun Zhang, Huanyu Chen, Anthony J. Murgo, Lori E. Dodd, Richard Pazdur, and Rajeshwari Sridhara

**HUMAN CANCER BIOLOGY**

2646  
**Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial**  
Mary W. Redman, Bryan H. Goldman, Michael LeBlanc, Anne Schott, and Laurence H. Baker

2657  
**Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes**  
Sucharitha Balasubramaniam, Clay E.S. Comstock, Adam Ertel, Kwang Won Jeong, Michael R. Stallcup, Sankar Addya, Peter A. McCue, William F. Ostrander Jr, Michael A. Augello, and Karen E. Knudsen

2668  
**Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations**  

**CANCER THERAPY: PRECLINICAL**

2677  
**Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor**  
Stela Álvarez-Fernández, Maria Jesús Ortiz-Ruiz, Tracy Parrott, Sara Zaknoon, Enrique M. Oxio, Jesús San Miguel, Francis J. Burrows, Azucena Esparis-Ogando, and Atanasio Pandiella

2688  
**Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer**  

*The Journal of Clinical and Translational Research May 15, 2013 • Volume 19 • Number 10*
Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways

Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2

IMAGING, DIAGNOSIS, PROGNOSIS
Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
Ke-Da Yu, Rui Zhu, Ming Zhan, Angel A. Rodriguez, Wei Yang, Stephen Wong, Andreas Makris, Brian D. Lehmann, Xi Chen, Ingrid Mayer, Jennifer A. Pietenpol, Zhi-Ming Shao, W. Fraser Symmans, and Jenny C. Chang

CANCER THERAPY: CLINICAL
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Anna Kanerva, Petri Nokisalmi, Iulia Diaconu, Annina Koski, Vincenzo Cerullo, Ilkka Liikanen, Sari Pesonen, Kalevi Kairemo, Sari Pesonen, Lotta Kangasniemi, and Akseli Hemminki

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE
Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

CORRECTION
Correction: Chromosome 5q Loss in Colorectal Flat Adenomas
ABOUT THE COVER

This image is taken from a bone metastasis in a patient with stage IV relapsed invasive CDH1 mutated lobular carcinoma of the breast. The tumor was negative for ERBB2 (HER2) amplification (FISH). The targeted next generation sequencing assay used in this study found an ERBB2-GRB7 putative gene fusion that has not been previously reported. The fusion retains the kinase domain of ERBB2 (uniprot.org) which suggests that it could result in ERBB2 activation. The 17q12-21 amplicon which includes both ERBB2 and GRB7 is frequently amplified in breast cancer and preclinical studies suggest that it may be a recombination hotspot. An expression screening study has reported that GRB7 can function as an ERBB2-dependent oncogene. GRB7 encodes an adaptor protein that interacts with ERBB2 and has been shown in a preclinical study to enhance its transformative capacity and increase ERBB2 phosphorylation in fibroblasts. For details, see the article by Ross and colleagues on page 2668 of this issue.

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org